Trinity Biotech plc Net Assets

Latest as of March 2026: $-71.98 Million USD

Trinity Biotech plc net assets. Based on the latest financial reports, Trinity Biotech plc (TRIB) has net assets worth $-71.98 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($105.17 Million) and total liabilities ($177.15 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore TRIB shareholders equity momentum to track the company's year-over-year net asset growth rate.

Key Net Assets Metrics

Metric	Value
Current Net Assets	$-71.98 Million
% of Total Assets	-68.45%
Annual Growth Rate	N/A
5-Year Change	N/A
10-Year Change	-166.2%
Growth Volatility	106.18

Net Assets of Trinity Biotech plc (1993–2025)

Net assets of Trinity Biotech plc from 1993 to 2025. This chart illustrates how Trinity Biotech plc's net assets have evolved over time, based on quarterly financial data. See Trinity Biotech plc net asset quality index to measure how much of total assets are equity-financed.

Annual Net Assets for Trinity Biotech plc (1993–2025)

The table below shows the annual net assets of Trinity Biotech plc from 1993 to 2025. For live market cap and overall valuation, see TRIB market cap overview.

Year	Net Assets	Change
2025-12-31	$-71.98 Million	-104.60%
2024-12-31	$-35.18 Million	-46.90%
2023-12-31	$-23.95 Million	-1000.60%
2022-12-31	$-2.18 Million	-582.13%
2021-12-31	$-319.00K	+85.62%
2020-12-31	$-2.22 Million	-147.08%
2019-12-31	$4.71 Million	-89.30%
2018-12-31	$44.05 Million	-32.43%
2017-12-31	$65.20 Million	-40.04%
2016-12-31	$108.73 Million	-49.17%
2015-12-31	$213.89 Million	+8.59%
2014-12-31	$196.97 Million	+7.63%
2013-12-31	$183.01 Million	+8.05%
2012-12-31	$169.38 Million	+11.93%
2011-12-31	$151.33 Million	+7.11%
2010-12-31	$141.29 Million	+78.07%
2009-12-31	$79.34 Million	+20.39%
2008-12-31	$65.91 Million	-51.84%
2007-12-31	$136.84 Million	-18.19%
2006-12-31	$167.26 Million	+25.18%
2005-12-31	$133.62 Million	+15.05%
2004-12-31	$116.14 Million	+44.70%
2003-12-31	$80.26 Million	+27.59%
2002-12-31	$62.91 Million	+11.28%
2001-12-31	$56.53 Million	+2.71%
2000-12-31	$55.04 Million	+142.25%
1999-12-31	$22.72 Million	+55.63%
1998-12-31	$14.60 Million	+105.63%
1997-12-31	$7.10 Million	-33.02%
1996-12-31	$10.60 Million	+41.33%
1995-12-31	$7.50 Million	+476.92%
1994-12-31	$1.30 Million	-58.06%
1993-12-31	$3.10 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Trinity Biotech plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 11206900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Trinity Biotech plc Net Assets Breakdown (December 2025)

Trinity Biotech plc net assets breakdown by equity component as of December 2025.

Component	Amount	Percentage
Common Stock	$40.00K	%
Other Comprehensive Income	$5.27 Million	%
Other Components	$38.88 Million	%
Total Equity	$-71.98 Million	100.00%

Trinity Biotech plc Competitors by Market Cap

The table below lists competitors of Trinity Biotech plc ranked by their market capitalization.

Company	Market Cap
Artemis Resources Ltd AU:ARV	$5.34 Million
Nacon S.A. PA:NACON	$5.34 Million
Instinct Bio Technical Company Holdings Inc. Ordinary Shares NASDAQ:BIOT	$5.34 Million
Brera Holdings PLC Class B Ordinary Shares NASDAQ:BREA	$5.34 Million
Zephyr Minerals Ltd V:ZFR	$5.33 Million
Nvni Group Limited Ordinary Shares NASDAQ:NVNI	$5.33 Million
Industronics Bhd KLSE:9393	$5.33 Million
Game Your Game, Inc. Common Stock NASDAQ:GYGY	$5.33 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Trinity Biotech plc's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from -35,181,000 to -71,982,000, a change of -36,801,000.
Net loss of 37,376,000 reduced equity.
New share issuances of 547,000 increased equity.
Other comprehensive income increased equity by 10,706,999.
Other factors decreased equity by 10,678,999.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	$-37.38 Million	-51.92%
Share Issuances	$547.00K	+0.76%
Other Comprehensive Income	$10.71 Million	+14.87%
Other Changes	$-10.68 Million	-14.84%
Total Change	$-	%

Book Value vs Market Value Analysis

This analysis compares Trinity Biotech plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
1993-12-31	$50.54	$6.56	x
1994-12-31	$15.57	$6.56	x
1995-12-31	$100.88	$6.56	x
1996-12-31	$142.58	$6.56	x
1997-12-31	$1.28	$6.56	x
1998-12-31	$196.39	$6.56	x
1999-12-31	$308.76	$6.56	x
2000-12-31	$22.28	$6.56	x
2001-12-31	$667.88	$6.56	x
2002-12-31	$24.67	$6.56	x
2003-12-31	$797.50	$6.56	x
2004-12-31	$878.05	$6.56	x
2005-12-31	$1366.56	$6.56	x
2006-12-31	$1531.72	$6.56	x
2007-12-31	$1079.84	$6.56	x
2008-12-31	$485.82	$6.56	x
2009-12-31	$568.52	$6.56	x
2010-12-31	$1000.45	$6.56	x
2011-12-31	$1066.08	$6.56	x
2012-12-31	$7.55	$6.56	x
2013-12-31	$7.81	$6.56	x
2014-12-31	$8.30	$6.56	x
2015-12-31	$1170.59	$6.56	x
2016-12-31	$19.21	$6.56	x
2017-12-31	$12.13	$6.56	x
2018-12-31	$8.51	$6.56	x
2019-12-31	$0.93	$6.56	x
2020-12-31	$-15.92	$6.56	x
2021-12-31	$-1.80	$6.56	x
2022-12-31	$-8.40	$6.56	x
2023-12-31	$-93.86	$6.56	x
2024-12-31	$-58.77	$6.56	x
2025-12-31	$-116.25	$6.56	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Trinity Biotech plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 0.00%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -85.36%
• Asset Turnover: 0.42x
• Equity Multiplier: 0.00x
Recent ROE (0.00%) is above the historical average (-18.12%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
1993	-141.67%	-141.67%	0.49x	2.04x	$-3.64 Million
1994	-253.85%	-63.46%	1.68x	2.38x	$-3.43 Million
1995	-10.67%	-8.08%	1.08x	1.23x	$-1.55 Million
1996	-8.49%	-12.50%	0.54x	1.26x	$-1.96 Million
1997	16.90%	7.14%	0.68x	3.46x	$490.00K
1998	17.81%	11.21%	0.52x	3.08x	$1.14 Million
1999	21.42%	18.83%	0.58x	1.96x	$2.62 Million
2000	8.76%	16.22%	0.44x	1.22x	$-680.80K
2001	2.58%	3.91%	0.48x	1.37x	$-4.17 Million
2002	7.96%	9.64%	0.58x	1.42x	$-1.28 Million
2003	7.22%	8.83%	0.56x	1.47x	$-2.23 Million
2004	4.45%	6.46%	0.53x	1.30x	$-6.45 Million
2005	3.95%	5.36%	0.53x	1.38x	$-8.08 Million
2006	1.96%	2.76%	0.48x	1.49x	$-13.45 Million
2007	-25.85%	-24.63%	0.66x	1.58x	$-49.06 Million
2008	-118.02%	-55.50%	1.08x	1.97x	$-84.37 Million
2009	14.90%	9.39%	0.95x	1.67x	$3.89 Million
2010	42.76%	67.40%	0.56x	1.14x	$46.29 Million
2011	10.30%	20.00%	0.45x	1.13x	$459.80K
2012	10.24%	21.02%	0.42x	1.17x	$403.00K
2013	5.65%	11.33%	0.40x	1.24x	$-7.96 Million
2014	8.74%	16.41%	0.43x	1.23x	$-2.48 Million
2015	10.19%	21.75%	0.28x	1.68x	$407.20K
2016	-92.55%	-101.02%	0.40x	2.30x	$-111.50 Million
2017	-61.77%	-40.62%	0.51x	2.95x	$-46.79 Million
2018	5.43%	2.46%	0.64x	3.43x	$-2.02 Million
2019	-86.27%	-4.50%	0.69x	27.81x	$-4.54 Million
2020	0.00%	-6.26%	0.78x	0.00x	$-6.17 Million
2021	0.00%	1.08%	0.68x	0.00x	$906.90K
2022	0.00%	-65.58%	0.68x	0.00x	$-40.78 Million
2023	0.00%	-42.26%	0.96x	0.00x	$-21.62 Million
2024	0.00%	-51.64%	0.60x	0.00x	$-28.27 Million
2025	0.00%	-85.36%	0.42x	0.00x	$-30.18 Million

Industry Comparison

This section compares Trinity Biotech plc's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

Industry: Medical Devices
Average net assets among peers: $296,528,539
Average return on equity (ROE) among peers: -35.30%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Trinity Biotech plc (TRIB)	$-71.98 Million	-141.67%	N/A	$5.33 Million
Abbott Laboratories (ABT)	$2.83 Billion	34.08%	0.96x	$190.23 Billion
Adagio Medical Holdings, Inc Common Stock (ADGM)	$-95.88 Million	0.00%	0.00x	$2.34 Million
Aethlon Medical Inc (AEMD)	$-3.66 Million	0.00%	0.00x	$1.11 Million
Acutus Medical Inc (AFIB)	$-11.59 Million	0.00%	0.00x	$903.35K
Adapthealth Corp (AHCO)	$15.14 Million	-140.98%	14.05x	$850.46 Million
20/20 Biolabs, Inc. Common Stock (AIDX)	$9.37 Million	23.33%	0.30x	$2.43 Million
Allurion Technologies, Inc. (ALUR)	$-77.98 Million	0.00%	0.00x	$21.01K
Autonomix Medical, Inc. Common Stock (AMIX)	$5.89 Million	-283.55%	0.29x	$1.61 Million
Artivion Inc (AORT)	$276.20 Million	-4.84%	1.86x	$1.03 Billion
Apyx Medical Inc (APYX)	$14.18 Million	18.92%	0.18x	$109.52 Million

About Trinity Biotech plc

NASDAQ:TRIB USA Medical Devices

Market Cap

$5.33 Million

Market Cap Rank

#28375 Global

#5843 in USA

Share Price

$6.56

Change (1 day)

-3.46%

52-Week Range

$0.30 - $13.38

All Time High

$67.65